Citations (201)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (33)
Maryam Daei, Golnaz Abbasi, Hossein Khalili & Zinat Heidari. (2022) Direct oral anticoagulants toxicity in children: an overview and practical guide. Expert Opinion on Drug Safety 21:9, pages 1183-1192.
Read now
Read now
Muhammad Maqsood, Muhammad Imran Hasan Khan, Mubashar Yameen, Kashif Aziz Ahmed, Nazim Hussain & Safdar Hussain. (2021) Use of oral rivaroxaban in cerebral venous thrombosis. Journal of Drug Assessment 10:1, pages 1-6.
Read now
Read now
Rafael Pereira de Andrade, Tamires Guedes Caldeira, Bárbara Vasconcelos Vasques, André Luís Morais Ruela & Jacqueline de Souza. (2021) Biopharmaceutics considerations for direct oral anticoagulants. Drug Development and Industrial Pharmacy 47:12, pages 1881-1894.
Read now
Read now
Emi Watanabe-Fujinuma, Benjamin F. Banderas, Yukihiro Koretsune, Koichiro Kumagai, Shinichiro Uchiyama, Takeshi Yamashita, Masahiro Yasaka, Sayako Akiyama, Jean-Baptiste Briere, Gavin Dickie & Stefan J. Cano. (2019) Psychometric validation of anti-clot treatment scale and treatment satisfaction questionnaire for medication version II in Japanese patients with atrial fibrillation. Journal of Medical Economics 22:8, pages 798-805.
Read now
Read now
Yukihiro Koretsune, Koichiro Kumagai, Shinichiro Uchiyama, Takeshi Yamashita, Masahiro Yasaka, Emi Watanabe-Fujinuma, Benjamin F. Banderas, Sayako Akiyama, Yutaka Okayama, Jean-Baptiste Briere, Gavin Dickie & Stefan J. Cano. (2018) Patient-reported treatment satisfaction with rivaroxaban in Japanese non-valvular atrial fibrillation patients: an observational study. Current Medical Research and Opinion 34:12, pages 2157-2164.
Read now
Read now
Hugo ten Cate, Yvonne MC Henskens & Marcus D Lancé. (2017) Practical guidance on the use of laboratory testing in the management of bleeding in patients receiving direct oral anticoagulants. Vascular Health and Risk Management 13, pages 457-467.
Read now
Read now
Walter Ageno, Jan Beyer-Westendorf & Andrea Rubboli. (2017) Once- versus twice-daily direct oral anticoagulants in non-valvular atrial fibrillation. Expert Opinion on Pharmacotherapy 18:13, pages 1325-1332.
Read now
Read now
Christos Voukalis, Gregory Y. H. Lip & Eduard Shantsila. (2016) Drug-drug interactions of non-vitamin K oral anticoagulants. Expert Opinion on Drug Metabolism & Toxicology 12:12, pages 1445-1461.
Read now
Read now
Ada Offurum, Lee-Ann Wagner & Tanisha Gooden. (2016) Adverse safety events in patients with Chronic Kidney Disease (CKD). Expert Opinion on Drug Safety 15:12, pages 1597-1607.
Read now
Read now
James Barton, Anselm Wong & Andis Graudins. (2016) Anti-Xa activity in apixaban overdose: a case report. Clinical Toxicology 54:9, pages 871-873.
Read now
Read now
Shant Shirvanian & Victor F. Tapson. (2015) Venous thromboembolism: identifying patients at risk and establishing prophylaxis. Current Medical Research and Opinion 31:12, pages 2297-2311.
Read now
Read now
Gines Escolar, Xavier Carne & Eduardo Arellano-Rodrigo. (2015) Dosing of rivaroxaban by indication: getting the right dose for the patient. Expert Opinion on Drug Metabolism & Toxicology 11:10, pages 1665-1677.
Read now
Read now
Ganesh Nallur Shivu & Nick Ossei-Gerning. (2014) Rivaroxaban in patients with a recent acute coronary syndrome event: integration of trial findings into clinical practice. Vascular Health and Risk Management 10, pages 291-302.
Read now
Read now
Sylvia Haas, Christoph Bode, Bo Norrving & Alexander GG Turpie. (2014) Practical guidance for using rivaroxaban in patients with atrial fibrillation: balancing benefit and risk. Vascular Health and Risk Management 10, pages 101-114.
Read now
Read now
Antonio Gómez-Outes, Mª Luisa Suárez-Gea, Ramón Lecumberri, Ana Isabel Terleira-Fernández & Emilio Vargas-Castrillón. (2014) Direct oral anticoagulants in the treatment of venous thromboembolism, with a focus on patients with pulmonary embolism: an evidence-based review. Vascular Health and Risk Management 10, pages 627-639.
Read now
Read now
Alexander GG Turpie. (2014) Rivaroxaban as an oral anticoagulant for stroke prevention in atrial fibrillation. Therapeutics and Clinical Risk Management 10, pages 197-205.
Read now
Read now
A. C. Camuglia, K. E. Waddell-Smith, C. J. Hammett & P. E. Aylward. (2014) The potential role of anticoagulant therapy for the secondary prevention of ischemic events post-acute coronary syndrome. Current Medical Research and Opinion 30:11, pages 2151-2167.
Read now
Read now
Peter P. Toth. (2014) Direct oral anticoagulants as alternative treatment options for the effective long-term treatment of patients with pulmonary embolism in primary care: a review. Annals of Medicine 46:6, pages 341-352.
Read now
Read now
Antonio Gómez-Outes, M Luisa Suárez-Gea, Ramón Lecumberri, Ana Isabel Terleira-Fernández, Emilio Vargas-Castrillón & Eduardo Rocha. (2013) Potential role of new anticoagulants for prevention and treatment of venous thromboembolism in cancer patients. Vascular Health and Risk Management 9, pages 207-228.
Read now
Read now
Anton Strunets, Mahek Mirza, Jasbir Sra & Arshad Jahangir. (2013) Novel anticoagulants for stroke prevention in atrial fibrillation: safety issues in the elderly. Expert Review of Clinical Pharmacology 6:6, pages 677-689.
Read now
Read now
Edelgard Lindhoff-Last, Jack Ansell, Theodore Spiro & Meyer Michel Samama. (2013) Laboratory testing of rivaroxaban in routine clinical practice: When, how, and which assays. Annals of Medicine 45:5-6, pages 423-429.
Read now
Read now
Sebastian Schellong. (2013) Anticoagulation with rivaroxaban: covering a broad spectrum of thromboembolic disease. Expert Review of Cardiovascular Therapy 11:7, pages 817-828.
Read now
Read now
Mariano A Giorgi & Lucas San Miguel. (2012) Rivaroxaban in atrial fibrillation. Vascular Health and Risk Management 8, pages 525-531.
Read now
Read now
Sebastian Werth, Kai Halbritter & Jan Beyer-Westendorf. (2012) Efficacy and safety of venous thromboembolism prophylaxis with apixaban in major orthopedic surgery. Therapeutics and Clinical Risk Management 8, pages 139-147.
Read now
Read now
Charles Mahan & Alex C. Spyropoulos. (2012) Improving prevention and treatment of venous thromboembolism: clinical trial results. Journal of Medical Economics 15:4, pages 611-622.
Read now
Read now
Lakshmi Gopalakrishnan, Varun Kumar, Payal Kohli, Priyamvada Singh, Ujjwal Rastogi & C. Michael Gibson. (2012) Pharmacokinetic evaluation of rivaroxaban for the treatment of acute coronary syndromes. Expert Opinion on Drug Metabolism & Toxicology 8:7, pages 889-900.
Read now
Read now
Thomas Goff, George Kontakis & Peter V Giannoudis. (2011) Safety and efficacy of rivaroxaban for thromboprophylaxis following lower limb surgery: an update. Expert Opinion on Drug Safety 10:5, pages 687-696.
Read now
Read now
Richard J Friedman, Nishan Sengupta & Michael Lees. (2011) Economic impact of venous thromboembolism after hip and knee arthroplasty: potential impact of rivaroxaban. Expert Review of Pharmacoeconomics & Outcomes Research 11:3, pages 299-306.
Read now
Read now
Deepu Alexander & Allen Jeremias. (2011) Rivaroxaban in the contemporary treatment of acute coronary syndromes. Expert Opinion on Investigational Drugs 20:6, pages 849-857.
Read now
Read now
Mariano A Giorgi, Hernán Cohen Arazi, Claudio D Gonzalez & Guillermo Di Girolamo. (2011) Changing anticoagulant paradigms for atrial fibrillation: dabigatran, apixaban and rivaroxaban. Expert Opinion on Pharmacotherapy 12:4, pages 567-577.
Read now
Read now
Lars C Borris. (2010) Emerging antithrombotic agents for thromboprophylaxis, clinical potential and patient considerations. Journal of Blood Medicine 1, pages 123-130.
Read now
Read now
Cecilia Becattini, Alessandra Lignani & Giancarlo Agnelli. (2010) New anticoagulants for the prevention of venous thromboembolism. Drug Design, Development and Therapy 4, pages 49-60.
Read now
Read now
Modesto de Candia, Gianfranco Lopopolo & Cosimo Altomare. (2009) Novel factor Xa inhibitors: a patent review. Expert Opinion on Therapeutic Patents 19:11, pages 1535-1580.
Read now
Read now
Articles from other publishers (168)
Solomiya Kyyak, Ali Jari, Diana Heimes, Julia Heider & Peer W. Kämmerer. (2023) Platelet-rich fibrin ensures hemostasis after single-tooth removal under factor Xa inhibitors — a clinical prospective randomized split-mouth study. Clinical Oral Investigations.
Crossref
Crossref
Chad E. Hatch & William J. Chain. (2023) Electrochemically Enabled Total Syntheses of Natural Products. ChemElectroChem.
Crossref
Crossref
Geoffrey Foulon-Pinto, Carmelo Lafuente-Lafuente, Georges Jourdi, Julien Le Guen, Fatoumata Tall, Etienne Puymirat, Maxime Delrue, Léa Rivière, Flora Ketz, Isabelle Gouin-Thibault, François Mullier, Pascale Gaussem, Eric Pautas, Thomas Lecompte, Emmanuel Curis & Virginie Siguret. (2022) Assessment of DOAC in GEriatrics (Adage Study): Rivaroxaban/Apixaban Concentrations and Thrombin Generation Profiles in NVAF Very Elderly Patients. Thrombosis and Haemostasis 123:04, pages 402-414.
Crossref
Crossref
Lucia Victoria Bortman, Florencia Mitchell, Sofia Naveiro, Juana Pérez Morales, Claudio Daniel Gonzalez, Guillermo Di Girolamo & Mariano Anibal Giorgi. (2023) Direct Oral Anticoagulants: An Updated Systematic Review of Their Clinical Pharmacology and Clinical Effectiveness and Safety in Patients With Nonvalvular Atrial Fibrillation. The Journal of Clinical Pharmacology 63:4, pages 383-396.
Crossref
Crossref
Bradley Casey, Abigail Daniels, Amol Bahekar, Divyang Patel & Alejandro Chapa-Rodriguez. (2023) Management of Massive Rivaroxaban Overdose With Acetaminophen and Isosorbide Mononitrate Overdose. Cureus.
Crossref
Crossref
Hong Duo, Yahui Li, Yujie Sun, Liang Wei, Ziqing Wang, Fang Fang, Yuxin Zhong, Jiao Huang, Linjie Luo, Zhiyong Peng & Huaqin Pan. (2022) Effect of therapeutic versus prophylactic anticoagulation therapy on clinical outcomes in COVID-19 patients: a systematic review with an updated meta-analysis. Thrombosis Journal 20:1.
Crossref
Crossref
Tayebeh Esmaeili, Mahmood Rezaee, Morteza Abdar Esfahani, Azadeh Davoudian, Dariush Omidfar & Saeed Rezaee. (2022) Rivaroxaban population pharmacokinetic and pharmacodynamic modeling in Iranian patients. Journal of Clinical Pharmacy and Therapeutics 47:8, pages 1284-1292.
Crossref
Crossref
Anselm Jorda, Jolanta M. Siller‐Matula, Markus Zeitlinger, Bernd Jilma & Georg Gelbenegger. (2021) Anticoagulant Treatment Regimens in Patients With Covid‐19: A Meta‐Analysis. Clinical Pharmacology & Therapeutics 111:3, pages 614-623.
Crossref
Crossref
Ye Tao, Xin Jiang, Ping Shi, Yanping Liu, Pingping Lin, Shuqin Liu, Ting Li, Yaping Ma, Xiaomeng Gao & Yu Cao. (2021) Bioequivalence and Food Effect Assessment of 2 Rivaroxaban Formulations in Healthy Chinese Volunteers: An Open, Randomized, Single‐Dose, and 4‐Period Crossover Study. Clinical Pharmacology in Drug Development 11:3, pages 358-363.
Crossref
Crossref
Krystle Lander, Priyanka Thakeria & Sachin Nayyar. (2021) Prophylactic anticoagulation in sinus rhythm for stroke prevention in cardiovascular disease: contemporary meta-analysis of large randomized trials. European Journal of Preventive Cardiology 28:17, pages 1939-1948.
Crossref
Crossref
Alireza Ghodsi, Leila Etemad, Bita Dadpour, Babak Mostafazadeh & Mohammad Moshiri. (2021) Conservative management of massive rivaroxaban overdose: A case report and literature review. Clinical Case Reports 9:11.
Crossref
Crossref
Shreya Arora, Shaalina Nair, Rishab Prabhu, Chaithanya Avanthika, Sharan Jhaveri, Shilpa Samayam, Maanya R Katta & Pahel Agarwal. (2021) Role of Direct Oral Anticoagulation Agents as Thromboprophylaxis in Antiphospholipid Syndrome. Cureus.
Crossref
Crossref
Jan Steffel, Ronan Collins, Matthias Antz, Pieter Cornu, Lien Desteghe, Karl Georg Haeusler, Jonas Oldgren, Holger Reinecke, Vanessa Roldan-Schilling, Nigel Rowell, Peter Sinnaeve, Thomas Vanassche, Tatjana Potpara, A John Camm, Hein Heidbüchel, Gregory Y H Lip, Thomas Deneke, Nikolaos Dagres, Giuseppe Boriani, Tze-Fan Chao, Eue-Keun Choi, Mellanie True Hills, Itamar de Souza Santos, Deirdre A Lane, Dan Atar, Boyoung Joung, Oana Maria Cole & Mark Field. (2021) 2021 European Heart Rhythm Association Practical Guide on the Use of Non-Vitamin K Antagonist Oral Anticoagulants in Patients with Atrial Fibrillation. EP Europace 23:10, pages 1612-1676.
Crossref
Crossref
Luisa Weiss, John Keaney, Paulina B. Szklanna, Tadhg Prendiville, Wido Uhrig, Kieran Wynne, Sarah Kelliher, Karl Ewins, Shane P. Comer, Karl Egan, Ellen O’Rourke, Eric Moran, Georgi Petrov, Ashish Patel, Áine Lennon, Alfonso Blanco, Barry Kevane, Sean Murphy, Fionnuala Ní Áinle & Patricia B. Maguire. (2021) Nonvalvular atrial fibrillation patients anticoagulated with rivaroxaban compared with warfarin exhibit reduced circulating extracellular vesicles with attenuated pro‐inflammatory protein signatures. Journal of Thrombosis and Haemostasis 19:10, pages 2583-2595.
Crossref
Crossref
Hyun Jin Oh, Kum Hei Ryu, Bum Joon Park & Byung-Ho Yoon. (2021) The risk of gastrointestinal hemorrhage with non-vitamin K antagonist oral anticoagulants. Medicine 100:11, pages e25216.
Crossref
Crossref
Rohi Shah, Nomaan Sheikh, Jitendra Mangwani, Nicolette Morgan & Hamidreza Khairandish. (2021) Direct oral anticoagulants (DOACs) and neck of femur fractures: Standardising the perioperative management and time to surgery. Journal of Clinical Orthopaedics and Trauma 12:1, pages 138-147.
Crossref
Crossref
Shujhat Khan, Hussein Elghazaly, Areeb Mian & Mansoor Khan. (2020) A meta-analysis on anticoagulation after vascular trauma. European Journal of Trauma and Emergency Surgery 46:6, pages 1291-1299.
Crossref
Crossref
Felix Stader, Hannah Kinvig, Melissa A. Penny, Manuel Battegay, Marco Siccardi & Catia Marzolini. (2019) Physiologically Based Pharmacokinetic Modelling to Identify Pharmacokinetic Parameters Driving Drug Exposure Changes in the Elderly. Clinical Pharmacokinetics 59:3, pages 383-401.
Crossref
Crossref
Chelsea Milito, Hannah McRae, Adrienne Victor, Majed A Refaai & Amy E Schmidt. (2019) Persistent Rivaroxaban Effect Due to Impaired Renal Clearance and Medication Effects. Laboratory Medicine.
Crossref
Crossref
Ahmed S. Yassin, Hossam Abubakar, Tushar Mishra, Omeralfaroug Adam, Melanie Hartman, Mohit Pahuja & Mohamed Shokr. (2019) Rivaroxaban for Left Ventricular Thrombus. American Journal of Therapeutics 26:4, pages e511-e515.
Crossref
Crossref
Adam Cuker, Allison Burnett, Darren Triller, Mark Crowther, Jack Ansell, Elizabeth M. Van Cott, Diane Wirth & Scott Kaatz. (2019) Reversal of direct oral anticoagulants: Guidance from the Anticoagulation Forum. American Journal of Hematology 94:6, pages 697-709.
Crossref
Crossref
Huanyu Zhou, Qi Wei, Haidi Wu, Minglong Tang, Shuo Yang, Yang Liu & Ling Qin. (2019) Efficacy of low-dose rivaroxaban in an 88-year-old female with pulmonary embolism. Medicine 98:20, pages e15705.
Crossref
Crossref
Ji Hyun Lee, Hong Euy Lim, Woo-Hyun Lim, Jinhee Ahn, Myung-Jin Cha, Junbeom Park, Ki Hong Lee, Hwan-Cheol Park, Eue-Keun Choi & Boyoung Joung. (2019) The 2018 Korean Heart Rhythm Society Practical Guidelines on the use of Non-Vitamin K-Antagonist Oral Anticoagulants: Bleeding Control and Perioperative Management. The Korean Journal of Medicine 94:1, pages 40-56.
Crossref
Crossref
Alice M. Kai, Nalini Vadivelu, Richard D. Urman, Shikha Shukla, Rob Schonberger & Trevor Banack. (2019) Perioperative Considerations in the Management of Anticoagulation Therapy for Patients Undergoing Surgery. Current Pain and Headache Reports 23:2.
Crossref
Crossref
Michael Mazzeffi & Ashleigh Lowery. 2019. Coronary and Cardiothoracic Critical Care. Coronary and Cardiothoracic Critical Care
474
498
.
Jen-Hung Huang, Yung-Kuo Lin, Cheng-Chih Chung, Ming-Hsiung Hsieh, Wan-Chun Chiu & Yi-Jen Chen. (2018) Factors That Determine the Prothrombin Time in Patients With Atrial Fibrillation Receiving Rivaroxaban. Clinical and Applied Thrombosis/Hemostasis 24:9_suppl, pages 188S-193S.
Crossref
Crossref
Paolo Gelosa, Laura Castiglioni, Marco Tenconi, Ludovico Baldessin, Giorgio Racagni, Alberto Corsini & Stefano Bellosta. (2018) Pharmacokinetic drug interactions of the non-vitamin K antagonist oral anticoagulants (NOACs). Pharmacological Research 135, pages 60-79.
Crossref
Crossref
Jonathan Ilicki, Jonas Höjer & Therese Djärv. (2018) Massive apixaban overdose – A comparison of three cases. The American Journal of Emergency Medicine 36:5, pages 891-893.
Crossref
Crossref
Siavash Piran, Caroline Gabriel & Sam Schulman. (2018) Prothrombin complex concentrate for reversal of direct factor Xa inhibitors prior to emergency surgery or invasive procedure: a retrospective study. Journal of Thrombosis and Thrombolysis 45:4, pages 486-495.
Crossref
Crossref
Jan Steffel, Peter Verhamme, Tatjana S Potpara, Pierre Albaladejo, Matthias Antz, Lien Desteghe, Karl Georg Haeusler, Jonas Oldgren, Holger Reinecke, Vanessa Roldan-Schilling, Nigel Rowell, Peter Sinnaeve, Ronan Collins, A John Camm, Hein Heidbüchel, Gregory Y H Lip, Jeffrey Weitz, Laurent Fauchier, Deirdre Lane, Giuseppe Boriani, Andreas Goette, Roberto Keegan, Robert MacFadyen, Chern-En Chiang, Boyoung Joung & Wataru Shimizu. (2018) The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. European Heart Journal 39:16, pages 1330-1393.
Crossref
Crossref
Samer Narouze, Honorio T. Benzon, David Provenzano, Asokumar Buvanendran, José De Andres, Timothy Deer, Richard Rauck & Marc A. Huntoon. (2017) Interventional Spine and Pain Procedures in Patients on Antiplatelet and Anticoagulant Medications (Second Edition). Regional Anesthesia and Pain Medicine, pages 1.
Crossref
Crossref
R. Kreutz, P.B. Persson, D. Kubitza, K. Thelen, S. Heitmeier, S. Schwers, M. Becka & M. Hemmrich. (2017) Dissociation between the pharmacokinetics and pharmacodynamics of once‐daily rivaroxaban and twice‐daily apixaban: a randomized crossover study. Journal of Thrombosis and Haemostasis 15:10, pages 2017-2028.
Crossref
Crossref
Lynn B. Oertel & Annemarie E. Fogerty. (2017) Use of direct oral anticoagulants for stroke prevention in elderly patients with nonvalvular atrial fibrillation. Journal of the American Association of Nurse Practitioners 29:9, pages 551-561.
Crossref
Crossref
Allyson Lemay, Alan D. Kaye & Richard D. Urman. (2017) Novel Anticoagulant Agents in the Perioperative Setting. Anesthesiology Clinics 35:2, pages 305-313.
Crossref
Crossref
Danilo Toni, Antonio Carolei, Valeria Caso, Domenico Consoli, Massimo Del Sette, Domenico Inzitari, Maurizio Melis, Giuseppe Micieli, Leandro Provinciali, Stefano Ricci, Paola Santalucia & Vito Toso. (2017) Use of rivaroxaban in patients with stroke. Neurological Sciences 38:5, pages 745-754.
Crossref
Crossref
Rohan Shah & Manesh R. Patel. (2016) Primary and key secondary results from the ROCKET AF trial, and their implications on clinical practice. Therapeutic Advances in Cardiovascular Disease 11:3, pages 105-120.
Crossref
Crossref
Susumu Tao, Kenichiro Otomo, Yuichi Ono, Yuki Osaka, Tatsuhiko Hirao, Kenji Koura, Tomoko Manno, Daisuke Ueshima, Shigeo Shimizu, Mitsuaki Isobe & Kenzo Hirao. (2016) Efficacy and safety of uninterrupted rivaroxaban taken preoperatively for radiofrequency catheter ablation of atrial fibrillation compared to uninterrupted warfarin. Journal of Interventional Cardiac Electrophysiology 48:2, pages 167-175.
Crossref
Crossref
Ka-Shing Cheung & Wai K Leung. (2017) Gastrointestinal bleeding in patients on novel oral anticoagulants: Risk, prevention and management. World Journal of Gastroenterology 23:11, pages 1954.
Crossref
Crossref
Robert B. Bolash & Richard W. Rosenquist. 2017. Complications of Regional Anesthesia. Complications of Regional Anesthesia
139
148
.
Jason P. Hecht & Wendy L. Wahl. 2017. Geriatric Trauma and Critical Care. Geriatric Trauma and Critical Care
405
414
.
Masatsugu Hori, Masayasu Matsumoto, Norio Tanahashi, Shin-ichi Momomura, Shinichiro Uchiyama, Shinya Goto, Tohru Izumi, Yukihiro Koretsune, Mariko Kajikawa, Masaharu Kato, Mary Cavaliere, Kazuma Iekushi & Satoshi Yamanaka. (2016) Predictive factors for bleeding during treatment with rivaroxaban and warfarin in Japanese patients with atrial fibrillation – Subgroup analysis of J-ROCKET AF. Journal of Cardiology 68:6, pages 523-528.
Crossref
Crossref
Hella Pfeiffer, Larissa Herbst, Bernd Schwarze, Reinhold Eckstein & Volker Weisbach. (2016) Massive intoxication with rivaroxaban, phenprocoumon, and diclofenac. Medicine 95:44, pages e5343.
Crossref
Crossref
James Uprichard. (2016) Management of rivaroxaban in relation to bodyweight and body mass index. Therapeutic Advances in Cardiovascular Disease 10:5, pages 294-303.
Crossref
Crossref
Enrico Bernardi, Giorgio Carbone & Francesco Dentali. (2016) How to manage patients on rivaroxaban in the emergency department. European Journal of Emergency Medicine 23:5, pages 320-329.
Crossref
Crossref
Sandeep Devabhakthuni, Connie H. Yoon & Kathleen J. Pincus. (2016) Review of the Target-Specific Oral Anticoagulants in Development for the Treatment and Prevention of Venous Thromboembolism. Journal of Pharmacy Practice 29:4, pages 392-405.
Crossref
Crossref
Christopher B. FordyceAnne S. HellkampYuliya LokhnyginaSamuel M. LindnerJonathan P. PicciniRichard C. BeckerScott D. BerkowitzGünter BreithardtKeith A. A. FoxKenneth W. MahaffeyChristopher C. NesselDaniel E. SingerManesh R. Patel. (2016) On-Treatment Outcomes in Patients With Worsening Renal Function With Rivaroxaban Compared With Warfarin. Circulation 134:1, pages 37-47.
Crossref
Crossref
Dagmar Kubitza, Scott D. Berkowitz & Frank Misselwitz. (2016) Evidence-Based Development and Rationale for Once-Daily Rivaroxaban Dosing Regimens Across Multiple Indications. Clinical and Applied Thrombosis/Hemostasis 22:5, pages 412-422.
Crossref
Crossref
Sotiris Antoniou & Walid Amara. (2016) Once-daily rivaroxaban for long-term stroke prevention in patients with atrial fibrillation. European Heart Journal Supplements 18:suppl D, pages D7-D15.
Crossref
Crossref
Henry A. Spiller, James B. Mowry, Alfred AleguasJr.Jr., Jill R.K. Griffith, Robert Goetz, Mark L. Ryan, Stacey Bangh, Wendy Klein-Schwartz, Scott Schaeffer & Marcel J. Casavant. (2016) An Observational Study of the Factor Xa Inhibitors Rivaroxaban and Apixaban as Reported to Eight Poison Centers. Annals of Emergency Medicine 67:2, pages 189-195.
Crossref
Crossref
Konstantinos N. Aronis & Elaine M. Hylek. (2015) Who, when, and how to reverse non-vitamin K oral anticoagulants. Journal of Thrombosis and Thrombolysis 41:2, pages 253-272.
Crossref
Crossref
Muhammed Sherid, Samian Sulaiman, Salih Samo, Husein Husein, Ruth Tupper, Charles Spurr, Humberto Sifuentes & Subbaramiah Sridhar. (2016) Risk of Gastrointestinal Bleeding with Rivaroxaban: A Comparative Study with Warfarin. Gastroenterology Research and Practice 2016, pages 1-9.
Crossref
Crossref
Maurizio Menichetti, Sebastiano Rosso, Elisa Menegatti & Maria Pazzaglia. (2015) Use of rivaroxaban in an elderly patient with intermediate-low early mortality risk due to pulmonary embolism: a case report. Journal of Medical Case Reports 9:1.
Crossref
Crossref
Ryan J. Spencer & John V. Amerena. (2015) Rivaroxaban in the Prevention of Stroke and Systemic Embolism in Patients with Non-Valvular Atrial Fibrillation: Clinical Implications of the ROCKET AF Trial and Its Subanalyses. American Journal of Cardiovascular Drugs 15:6, pages 395-401.
Crossref
Crossref
Hein Heidbuchel, Peter Verhamme, Marco Alings, Matthias Antz, Hans-Christoph Diener, Werner Hacke, Jonas Oldgren, Peter Sinnaeve, A. John Camm & Paulus Kirchhof. (2015) Updated European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist anticoagulants in patients with non-valvular atrial fibrillation. Europace 17:10, pages 1467-1507.
Crossref
Crossref
Mustafa Çelebier, Tuba Reçber, Engin Koçak, Sacide Altınöz & Sedef Kır. (2015) Determination of Rivaroxaban in Human Plasma by Solid-Phase Extraction–High Performance Liquid Chromatography. Journal of Chromatographic Science, pages bmv135.
Crossref
Crossref
A. Tas Tuna, O. Palabiyik & S. G. Beyaz. (2015) Retracted: Spontaneous rectus sheath haematoma associated with rivaroxaban treatment. Journal of Clinical Pharmacy and Therapeutics 40:4, pages 486-488.
Crossref
Crossref
Sebastian Werth, Tomás Breslin, Fionnuala NiAinle & Jan Beyer-Westendorf. (2015) Bleeding Risk, Management and Outcome in Patients Receiving Non-VKA Oral Anticoagulants (NOACs). American Journal of Cardiovascular Drugs 15:4, pages 235-242.
Crossref
Crossref
Sotiris Antoniou. (2015) Rivaroxaban for the treatment and prevention of thromboembolic disease. Journal of Pharmacy and Pharmacology 67:8, pages 1119-1132.
Crossref
Crossref
Robert C. WoodIIIIII, David W. Stewart, Lindsey Slusher, Hadi El-Bazouni, David Cluck, Jessica Freshour & Brian Odle. (2015) Retrospective Evaluation of Postoperative Bleeding Events in Patients Receiving Rivaroxaban After Undergoing Total Hip and Total Knee Arthroplasty: Comparison with Clinical Trial Data. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy 35:7, pages 663-669.
Crossref
Crossref
Juan I. Arcelus, Pere Domènech, Ma del Carmen Fernández-Capitan, Ricardo Guijarro, David Jiménez, Sonia Jiménez, Francisco S. Lozano, Manel Monreal, José A. Nieto & José A. Páramo. (2014) Rivaroxaban in the Treatment of Venous Thromboembolism and the Prevention of Recurrences. Clinical and Applied Thrombosis/Hemostasis 21:4, pages 297-308.
Crossref
Crossref
Davide Imberti & Raffaella Benedetti. (2013) Practical Management of Rivaroxaban for the Treatment of Venous Thromboembolism. Clinical and Applied Thrombosis/Hemostasis 21:4, pages 309-318.
Crossref
Crossref
P. Vranckx, F. W. G. Leebeek, J. G. P. Tijssen, J. Koolen, F. Stammen, J.-P. R. Herman, R. J. de Winter, A. W. J. van t Hof, B. Backx, W. Lindeboom, S.-Y. Kim, B. Kirsch, M. van Eickels, F. Misselwitz & F. W. A. Verheugt. (2015) Peri-procedural use of rivaroxaban in elective percutaneous coronary intervention to treat stable coronary artery disease. Thrombosis and Haemostasis 114:2, pages 258-267.
Crossref
Crossref
Arun Krishnamoorthy, Matthew W. Sherwood, Renato D. Lopes & Richard C. Becker. (2015) The periprocedural management of novel oral anticoagulants in patients with nonvalvular atrial fibrillation: Rationale and a summary of the available evidence from phase 3 clinical trials. American Heart Journal 169:3, pages 315-322.
Crossref
Crossref
Alexander Mensch, Stephanie Stock, Björn Stollenwerk & Dirk Müller. (2014) Cost Effectiveness of Rivaroxaban for Stroke Prevention in German Patients with Atrial Fibrillation. PharmacoEconomics 33:3, pages 271-283.
Crossref
Crossref
Paolo Prandoni, Martin H. Prins, Alexander T. Cohen, Katharina Müller, Ákos F. Pap, Miriam C. Tewes & Anthonie W. A. Lensing. (2015)
Use of Prestudy Heparin Did Not Influence the Efficacy and Safety of Rivaroxaban in Patients Treated for Symptomatic Venous Thromboem‐bolism in the
EINSTEIN DVT
and
EINSTEIN PE
Studies
. Academic Emergency Medicine 22:2, pages 142-149.
Crossref
Crossref
J. Harenberg, V. A.-T. Hentschel, S. Du, S. Zolfaghari, R. Krämer, C. Weiss, B. K. Krämer & M. Wehling. (2017) Anticoagulation in patients with impaired renal function and with haemodialysis. Hämostaseologie 35:01, pages 77-83.
Crossref
Crossref
Michael Mazzeffi & Ashleigh Lowery. 2015. Modern Concepts and Practices in Cardiothoracic Critical Care. Modern Concepts and Practices in Cardiothoracic Critical Care
253
277
.
Samer Narouze, Honorio T. Benzon, David A. Provenzano, Asokumar Buvanendran, José De Andres, Timothy R. Deer, Richard Rauck & Marc A. Huntoon. (2015) Interventional Spine and Pain Procedures in Patients on Antiplatelet and Anticoagulant Medications. Regional Anesthesia and Pain Medicine 40:3, pages 182-212.
Crossref
Crossref
Michael Levine & Joshua N. Goldstein. (2014) Bleeding complications of targeted oral anticoagulants: what is the risk?. Hematology 2014:1, pages 504-509.
Crossref
Crossref
Walter Ageno, Lorenzo G Mantovani, Sylvia Haas, Reinhold Kreutz, Verena Haupt, Jonas Schneider & Alexander GG Turpie. (2014) XALIA: rationale and design of a non-interventional study of rivaroxaban compared with standard therapy for initial and long-term anticoagulation in deep vein thrombosis. Thrombosis Journal 12:1.
Crossref
Crossref
Hideyuki Ishihara, Hiroaki Torii, Hirochika Imoto, Fumiaki Oka, Hirokazu Sadahiro & Michiyasu Suzuki. (2014) Intravenous Thrombolysis with Recombinant Tissue Plasminogen Activator in a Stroke Patient Treated with Rivaroxaban. Journal of Stroke and Cerebrovascular Diseases 23:10, pages e457-e459.
Crossref
Crossref
Satoshi Ogawa, Takanori Ikeda, Takanari Kitazono, Jyoji Nakagawara, Kazuo Minematsu, Susumu Miyamoto, Yuji Murakawa, Kazuma Iekushi, Satoshi Yamanaka, Takashi Yamada & Lyo Inuyama. (2014) Present Profiles of Novel Anticoagulant Use in Japanese Patients with Atrial Fibrillation: Insights from the Rivaroxaban Postmarketing Surveillance Registry. Journal of Stroke and Cerebrovascular Diseases 23:10, pages 2520-2526.
Crossref
Crossref
Anna Plitt & Robert P. Giugliano. (2014) Edoxaban. Journal of Cardiovascular Pharmacology and Therapeutics 19:5, pages 409-416.
Crossref
Crossref
L.‐A. Linkins & K. Moffat. (2014) Monitoring the anticoagulant effect after a massive rivaroxaban overdose. Journal of Thrombosis and Haemostasis 12:9, pages 1570-1571.
Crossref
Crossref
Luis Jara-Palomares, Raquel Sanchez-Oro-Gomez, Teresa Elias-Hernandez, Raquel Morillo-Guerrero, Marta Ferrer-Galvan, Maria Isabel Asensio-Cruz, Emilia Barrot-Cortes & Remedios Otero-Candelera. (2014) Rivaroxaban for the treatment of venous thromboembolism. A “real-life” perspective in 103 patients. Thrombosis Research 134:3, pages 617-621.
Crossref
Crossref
Eric Anderson, Cornelius Dyke & Jerrold H. Levy. (2014) Anticoagulation Strategies for the Management of Postoperative Atrial Fibrillation. Clinics in Laboratory Medicine 34:3, pages 537-561.
Crossref
Crossref
Lance A. WilliamsIIIIII, James M. HunterJr.Jr., Marisa B. Marques & Thomas R. Vetter. (2014) Periprocedural Management of Patients on Anticoagulants. Clinics in Laboratory Medicine 34:3, pages 595-611.
Crossref
Crossref
Toby Trujillo & Paul P. Dobesh. (2014) Clinical Use of Rivaroxaban: Pharmacokinetic and Pharmacodynamic Rationale for Dosing Regimens in Different Indications. Drugs 74:14, pages 1587-1603.
Crossref
Crossref
Paolo Prandoni. (2014) Treatment of patients with acute deep vein thrombosis and/or pulmonary embolism: Efficacy and safety of non-VKA oral anticoagulants in selected populations. Thrombosis Research 134:2, pages 227-233.
Crossref
Crossref
Michael Levine & Joshua N. Goldstein. (2014) Emergency Reversal of Anticoagulation: Novel Agents. Current Neurology and Neuroscience Reports 14:8.
Crossref
Crossref
Reinhold Kreutz. (2013) A clinical and pharmacologic assessment of once-daily versus twice-daily dosing for rivaroxaban. Journal of Thrombosis and Thrombolysis 38:2, pages 137-149.
Crossref
Crossref
I.G. Girgis, M.R. Patel, G.R. Peters, K.T. Moore, K.W. Mahaffey, C.C. Nessel, J.L. Halperin, R.M. Califf, K.A.A. Fox & R.C. Becker. (2014) Population pharmacokinetics and pharmacodynamics of rivaroxaban in patients with non‐valvular atrial fibrillation: Results from ROCKET AF. The Journal of Clinical Pharmacology 54:8, pages 917-927.
Crossref
Crossref
Cecilia Corros, Elena Velasco & Ana Fidalgo. (2014) Resultados de los nuevos anticoagulantes orales en fibrilación auricular no valvular. Cardiocore 49:3, pages 91-94.
Crossref
Crossref
A. Jalota, T. M. Scarabelli, L. Saravolatz, M. U. Bakhsh, P. Agrawal, R. Jalota, C. Chen-Scarabelli, V. Fuster & J. Halperin. (2014) Novel Anticoagulants for Stroke Prevention in Patients with Atrial Fibrillation. Cardiovascular Drugs and Therapy 28:3, pages 247-262.
Crossref
Crossref
Masayasu Matsumoto, Masatsugu Hori, Norio Tanahashi, Shin-ichi Momomura, Shinichiro Uchiyama, Shinya Goto, Tohru Izumi, Yukihiro Koretsune, Mariko Kajikawa, Masaharu Kato, Hitoshi Ueda, Kazuma Iekushi, Satoshi Yamanaka & Masahiro Tajiri. (2014) Rivaroxaban versus warfarin in Japanese patients with non-valvular atrial fibrillation in relation to hypertension: a subgroup analysis of the J-ROCKET AF trial. Hypertension Research 37:5, pages 457-462.
Crossref
Crossref
Shinichiro Uchiyama, Masatsugu Hori, Masayasu Matsumoto, Norio Tanahashi, Shin-ichi Momomura, Shinya Goto, Tohru Izumi, Yukihiro Koretsune, Mariko Kajikawa, Masaharu Kato, Hitoshi Ueda, Kazuma Iekushi, Satoshi Yamanaka & Masahiro Tajiri. (2014) Net Clinical Benefit of Rivaroxaban versus Warfarin in Japanese Patients with Nonvalvular Atrial Fibrillation: A Subgroup Analysis of J-ROCKET AF. Journal of Stroke and Cerebrovascular Diseases 23:5, pages 1142-1147.
Crossref
Crossref
J. W. Cheng & G. Barillari. (2014) Non-vitamin K antagonist oral anticoagulants in cardiovascular disease management: evidence and unanswered questions. Journal of Clinical Pharmacy and Therapeutics 39:2, pages 118-135.
Crossref
Crossref
Carl-Erik Dempfle. (2014) Direct Oral Anticoagulants—Pharmacology, Drug Interactions, and Side Effects. Seminars in Hematology 51:2, pages 89-97.
Crossref
Crossref
Elisabeth Perzborn, Stefan Heitmeier, Volker Laux & Anja Buchmüller. (2014) Reversal of rivaroxaban-induced anticoagulation with prothrombin complex concentrate, activated prothrombin complex concentrate and recombinant activated factor VII in vitro. Thrombosis Research 133:4, pages 671-681.
Crossref
Crossref
Carlos J. Gonzalez-Quesada & Robert P. Giugliano. (2014) Comparison of the Phase III Clinical Trial Designs of Novel Oral Anticoagulants Versus Warfarin for the Treatment of Nonvalvular Atrial Fibrillation: Implications for Clinical Practice. American Journal of Cardiovascular Drugs 14:2, pages 111-127.
Crossref
Crossref
Dhanunjaya Lakkireddy, Yeruva Madhu Reddy, Luigi Di Biase, Ajay Vallakati, Moussa C. Mansour, Pasquale Santangeli, Sandeep Gangireddy, Vijay Swarup, Fadi Chalhoub, Donita Atkins, Sudharani Bommana, Atul Verma, Javier E. Sanchez, J. David Burkhardt, Conor D. Barrett, Salwa Baheiry, Jeremy Ruskin, Vivek Reddy & Andrea Natale. (2014) Feasibility and Safety of Uninterrupted Rivaroxaban for Periprocedural Anticoagulation in Patients Undergoing Radiofrequency Ablation for Atrial Fibrillation. Journal of the American College of Cardiology 63:10, pages 982-988.
Crossref
Crossref
Greg L. Plosker. (2014) Rivaroxaban: A Review of Its Use in Acute Coronary Syndromes. Drugs 74:4, pages 451-464.
Crossref
Crossref
Daniel Kim, Richard Barna, Mary Barna Bridgeman & Luigi Brunetti. (2013) Novel Oral Anticoagulants for Stroke Prevention in the Geriatric Population. American Journal of Cardiovascular Drugs 14:1, pages 15-29.
Crossref
Crossref
Masatsugu Hori, Masayasu Matsumoto, Norio Tanahashi, Shin-ichi Momomura, Shinichiro Uchiyama, Shinya Goto, Tohru Izumi, Yukihiro Koretsune, Mariko Kajikawa, Masaharu Kato, Hitoshi Ueda, Kazuma Iekushi, Satoshi Yamanaka & Masahiro Tajiri. (2014) Rivaroxaban vs. Warfarin in Japanese Patients With Non-Valvular Atrial Fibrillation in Relation to Age. Circulation Journal 78:6, pages 1349-1356.
Crossref
Crossref
Jürgen Koscielny & Edita Rutkauskaite. (2014) Rivaroxaban and Hemostasis in Emergency Care. Emergency Medicine International 2014, pages 1-9.
Crossref
Crossref
Wolfgang Mueck, Jan Stampfuss, Dagmar Kubitza & Michael Becka. (2013) Clinical Pharmacokinetic and Pharmacodynamic Profile of Rivaroxaban. Clinical Pharmacokinetics 53:1, pages 1-16.
Crossref
Crossref
Patrick Goldstein, Ismaïl Elalamy, Kurt Huber, Nicolas Danchin & Eric Wiel. (2013) Rivaroxaban and other non-vitamin K antagonist oral anticoagulants in the emergency treatment of thromboembolism. International Journal of Emergency Medicine 6:1.
Crossref
Crossref
Vijay V. Upreti, Jessie Wang, Yu Chen Barrett, Wonkyung Byon, Rebecca A. Boyd, Janice Pursley, Frank P. LaCreta & Charles E. Frost. (2013) Effect of extremes of body weight on the pharmacokinetics, pharmacodynamics, safety and tolerability of apixaban in healthy subjects. British Journal of Clinical Pharmacology 76:6, pages 908-916.
Crossref
Crossref
H.T. Benzon, M.J. Avram, D. Green & R.O. Bonow. (2013) New oral anticoagulants and regional anaesthesia. British Journal of Anaesthesia 111, pages i96-i113.
Crossref
Crossref
W. Klauser & M. Dütsch. (2013) Practical management of new oral anticoagulants after total hip or total knee arthroplasty. MUSCULOSKELETAL SURGERY 97:3, pages 189-197.
Crossref
Crossref
Norio Tanahashi, Masatsugu Hori, Masayasu Matsumoto, Shin-ichi Momomura, Shinichiro Uchiyama, Shinya Goto, Tohru Izumi, Yukihiro Koretsune, Mariko Kajikawa, Masaharu Kato, Hitoshi Ueda, Kazuya Iwamoto & Masahiro Tajiri. (2013) Rivaroxaban versus Warfarin in Japanese Patients with Nonvalvular Atrial Fibrillation for the Secondary Prevention of Stroke: A Subgroup Analysis of J-ROCKET AF. Journal of Stroke and Cerebrovascular Diseases 22:8, pages 1317-1325.
Crossref
Crossref
Gwen M. Bernacki & Richard C. Becker. (2013) Oral anticoagulants in older adults with atrial fibrillation. Journal of Thrombosis and Thrombolysis 36:4, pages 403-415.
Crossref
Crossref
Emine Gazi, Ahmet Temiz, Ahmet Barutcu & Yucel Colkesen. (2013) Novel Therapeutics for Thromboprophylaxis in Nonvalvular Atrial Fibrillation. Drug Development Research 74:7, pages 485-491.
Crossref
Crossref
Sascha Meyer dos Santos, Anita Zorn, Zeno Guttenberg, Bettina Picard-Willems, Christina Kläffling, Karen Nelson, Ute Klinkhardt & Sebastian Harder. (2013) A novel μ-fluidic whole blood coagulation assay based on Rayleigh surface-acoustic waves as a point-of-care method to detect anticoagulants. Biomicrofluidics 7:5.
Crossref
Crossref
Sebastian Harder & Jochen Graff. (2013) Novel oral anticoagulants: clinical pharmacology, indications and practical considerations. European Journal of Clinical Pharmacology 69:9, pages 1617-1633.
Crossref
Crossref
Jay Desai, Christopher B. Granger, Jeffrey I. Weitz & James Aisenberg. (2013) Novel oral anticoagulants in gastroenterology practice. Gastrointestinal Endoscopy 78:2, pages 227-239.
Crossref
Crossref
Surekha Maddula & Jack Ansell. (2013) Target specific oral anticoagulants in the management of thromboembolic disease in the elderly. Journal of Thrombosis and Thrombolysis 36:2, pages 203-211.
Crossref
Crossref
Troy C. Sarich, Gary Peters, Scott D. Berkowitz, Frank Misselwitz, Christopher C. Nessel, Paul Burton, Nancy Cook-Bruns, Anthonie W.A. Lensing, Lloyd Haskell, Elisabeth Perzborn, Dagmar Kubitza, Kenneth T. Moore, Sanjay Jalota, Juergen Weber, Guohua Pan, Xiang Sun, Torsten Westermeier, Andrea Nadel, Leonard Oppenheimer & Peter M. DiBattiste. (2013) Rivaroxaban: a novel oral anticoagulant for the prevention and treatment of several thrombosis-mediated conditions. Annals of the New York Academy of Sciences 1291:1, pages 42-55.
Crossref
Crossref
Kelechi C. Ogbonna & Sean M. Jeffery. (2013) Risk versus Benefit of Non-Vitamin K Dependent Anticoagulants Compared to Warfarin for the Management of Atrial Fibrillation in the Elderly. Drugs & Aging 30:7, pages 513-525.
Crossref
Crossref
Dagmar Kubitza, Michael Becka, Stephan Schwers & Barbara Voith. (2013) Investigation of Pharmacodynamic and Pharmacokinetic Interactions Between Rivaroxaban and Enoxaparin in Healthy Male Subjects. Clinical Pharmacology in Drug Development 2:3, pages 270-277.
Crossref
Crossref
Hein Heidbuchel, Peter Verhamme, Marco Alings, Matthias Antz, Werner Hacke, Jonas Oldgren, Peter Sinnaeve, A. John Camm & Paulus Kirchhof. (2013) European Heart Rhythm Association Practical Guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation. EP Europace 15:5, pages 625-651.
Crossref
Crossref
Dagmar Kubitza, Michael Becka, Angelika Roth & Wolfgang Mueck. (2013) The Influence of Age and Gender on the Pharmacokinetics and Pharmacodynamics of Rivaroxaban-An Oral, Direct Factor Xa Inhibitor. The Journal of Clinical Pharmacology 53:3, pages 249-255.
Crossref
Crossref
Francesco Scaglione. (2013) New Oral Anticoagulants: Comparative Pharmacology with Vitamin K Antagonists. Clinical Pharmacokinetics 52:2, pages 69-82.
Crossref
Crossref
Masato Kaneko, Takahiko Tanigawa, Kensei Hashizume, Mariko Kajikawa, Masahiro Tajiri & Wolfgang Mueck. (2013) Confirmation of Model-based Dose Selection for a Japanese Phase III Study of Rivaroxaban in Non-valvular Atrial Fibrillation Patients. Drug Metabolism and Pharmacokinetics 28:4, pages 321-331.
Crossref
Crossref
Takahiko Tanigawa, Masato Kaneko, Kensei Hashizume, Mariko Kajikawa, Hitoshi Ueda, Masahiro Tajiri, John F. Paolini & Wolfgang Mueck. (2013) Model-based Dose Selection for Phase III Rivaroxaban Study in Japanese Patients with Non-valvular Atrial Fibrillation. Drug Metabolism and Pharmacokinetics 28:1, pages 59-70.
Crossref
Crossref
Faryal Tahir, Haris Riaz, Talha Riaz, Maaz B Badshah, Irbaz B Riaz, Ameer Hamza & Hafsa Mohiuddin. (2013) The new oral anti-coagulants and the phase 3 clinical trials - a systematic review of the literature. Thrombosis Journal 11:1, pages 18.
Crossref
Crossref
Nay Min Tun & Thein Hlaing Oo. (2013) Prevention and Treatment of Venous Thromboembolism with New Oral Anticoagulants: A Practical Update for Clinicians. Thrombosis 2013, pages 1-10.
Crossref
Crossref
Tyan F. Thomas, Valerie Ganetsky & Sarah A. Spinler. (2013) Rivaroxaban: An Oral Factor Xa Inhibitor. Clinical Therapeutics 35:1, pages 4-27.
Crossref
Crossref
Christopher Patriquin & Mark Crowther. 2013. Consultative Hemostasis and Thrombosis. Consultative Hemostasis and Thrombosis
477
495
.
Enrique Jiménez-Varo, Marisa Cañadas-Garre, Margarita Aguilera, Desiree Gonzalez Callejas, Cristina Perez Ramirez & Miguel A. Calleja Hernández. 2013. Omics for Personalized Medicine. Omics for Personalized Medicine
435
467
.
Mark J Alberts, John W Eikelboom & Graeme J Hankey. (2012) Antithrombotic therapy for stroke prevention in non-valvular atrial fibrillation. The Lancet Neurology 11:12, pages 1066-1081.
Crossref
Crossref
Alexander G.G. Turpie. (2012) Advances in oral anticoagulation treatment: the safety and efficacy of rivaroxaban in the prevention and treatment of thromboembolism. Therapeutic Advances in Hematology 3:5, pages 309-323.
Crossref
Crossref
Calvin H. YehJames C. FredenburghJeffrey I. Weitz. (2012) Oral Direct Factor Xa Inhibitors. Circulation Research 111:8, pages 1069-1078.
Crossref
Crossref
A. G. G. Turpie, R. Kreutz, J. Llau, B. Norrving & S. Haas. (2012) Management consensus guidance for the use of rivaroxaban – an oral, direct factor Xa inhibitor. Thrombosis and Haemostasis 108:5, pages 876-886.
Crossref
Crossref
Ludmila Katherine Martin & Tanios Bekaii-Saab. (2012) Management of Venous Thromboembolism in Patients with Advanced Gastrointestinal Cancers: What Is the Role of Novel Oral Anticoagulants?. Thrombosis 2012, pages 1-9.
Crossref
Crossref
Danai Khemasuwan & Nuttanun Suramaethakul. (2012) Novel Oral Anticoagulation in Management of Venous Thromboembolism, Atrial Fibrillation, and Acute Coronary Syndrome. Clinical and Applied Thrombosis/Hemostasis 18:5, pages 476-486.
Crossref
Crossref
Edith Nutescu. (2012) Apixaban: A novel oral inhibitor of factor Xa. American Journal of Health-System Pharmacy 69:13, pages 1113-1126.
Crossref
Crossref
Xu Steven Xu, Kenneth Moore, Paul Burton, Kim Stuyckens, Wolfgang Mueck, Stefaan Rossenu, Alexei Plotnikov, Michael Gibson & An Vermeulen. (2012) Population pharmacokinetics and pharmacodynamics of rivaroxaban in patients with acute coronary syndromes. British Journal of Clinical Pharmacology 74:1, pages 86-97.
Crossref
Crossref
Louis M. Kwong. (2012) Rivaroxaban, an Oral, Direct Factor Xa Inhibitor: A New Option for Thromboprophylaxis. Orthopedics 35:6.
Crossref
Crossref
Graeme J. Hankey. (2012) Anticoagulant therapy for patients with ischaemic stroke. Nature Reviews Neurology 8:6, pages 319-328.
Crossref
Crossref
C.-E. Dempfle. (2012) Pharmakologie der neuen oralen AntikoagulanzienPharmacology of the new oral anticoagulants. Herz 37:4, pages 362-369.
Crossref
Crossref
Nicholas B Norgard, James J DiNicolantonio, Taylor J Topping & Benjamin Wee. (2012) Novel anticoagulants in atrial fibrillation stroke prevention. Therapeutic Advances in Chronic Disease 3:3, pages 123-136.
Crossref
Crossref
Dennis J. Cada, Terri L. Levien & Danial E. Baker. (2012) Rivaroxaban in Nonvalvular Atrial Fibrillation. Hospital Pharmacy 47:4, pages 293-304.
Crossref
Crossref
Meyer Michel Samama, Genevieve Contant, Theodore E. Spiro, Elisabeth Perzborn, Lena Le Flem, Céline Guinet, Yves Gourmelin & Jean Luc Martinoli. (2012) Evaluation of the Prothrombin Time for Measuring Rivaroxaban Plasma Concentrations Using Calibrators and Controls. Clinical and Applied Thrombosis/Hemostasis 18:2, pages 150-158.
Crossref
Crossref
Paolo Prandoni. (2012) Healthcare burden associated with the post‐thrombotic syndrome and potential impact of the new oral anticoagulants. European Journal of Haematology 88:3, pages 185-194.
Crossref
Crossref
J.-P. Bassand. (2012) Review of atrial fibrillation outcome trials of oral anticoagulant and antiplatelet agents. Europace 14:3, pages 312-324.
Crossref
Crossref
Joseph A. Grillo, Ping Zhao, Julie Bullock, Brian P. Booth, Min Lu, Kathy Robie-Suh, Eva Gil Berglund, K. Sandy Pang, Atiqur Rahman, Lei Zhang, Lawrence J. Lesko & Shiew-Mei Huang. (2012) Utility of a physiologically-based pharmacokinetic (PBPK) modeling approach to quantitatively predict a complex drug-drug-disease interaction scenario for rivaroxaban during the drug review process: implications for clinical practice. Biopharmaceutics & Drug Disposition 33:2, pages 99-110.
Crossref
Crossref
Walter Ageno, Alexander S. Gallus, Ann Wittkowsky, Mark Crowther, Elaine M. Hylek & Gualtiero Palareti. (2012) Oral Anticoagulant Therapy. Chest 141:2, pages e44S-e88S.
Crossref
Crossref
Reinhold Kreutz. (2011) Pharmacodynamic and pharmacokinetic basics of rivaroxaban. Fundamental & Clinical Pharmacology 26:1, pages 27-32.
Crossref
Crossref
Rupert M. Bauersachs. (2012) Use of anticoagulants in elderly patients. Thrombosis Research 129:2, pages 107-115.
Crossref
Crossref
R. Callif, J. Alexander, R. Giugliano, A. Turpie & J.-P. Kevorkian. (2012) Rivaroxaban: un anti-thrombotique original. Archives des Maladies du Coeur et des Vaisseaux - Pratique 2012:205, pages 13-15.
Crossref
Crossref
T. Helbing, C. Bode & M. Moser. (2017) Rivaroxaban in der Prävention und Therapie thromboembolischer Erkrankungen. Hämostaseologie 32:03, pages 195-202.
Crossref
Crossref
John P. Fletcher. 2012. Insall & Scott Surgery of the Knee. Insall & Scott Surgery of the Knee
e137-1
e137-6
.
J. Cada Dennis, L. Levien Terri, R. Woodruff Christopher & E. Baker Danial. (2011) Rivaroxaban. Hospital Pharmacy 46:12, pages 960-970.
Crossref
Crossref
Kenneth Todd Moore, Alexei Nikolaevich Plotnikov, An Thyssen, Nicole Vaccaro, Jay Ariyawansa & Paul Bryan Burton. (2011) Effect of Multiple Doses of Omeprazole on the Pharmacokinetics, Pharmacodynamics, and Safety of a Single Dose of Rivaroxaban. Journal of Cardiovascular Pharmacology 58:6, pages 581-588.
Crossref
Crossref
Wolfgang Mueck, Anthonie W.A. Lensing, Giancarlo Agnelli, Hervé Decousus, Paolo Prandoni & Frank Misselwitz. (2011) Rivaroxaban. Clinical Pharmacokinetics 50:10, pages 675-686.
Crossref
Crossref
S. H. Hohnloser & S. J. Connolly. (2011) Atrial fibrillation, moderate chronic kidney disease, and stroke prevention: new anticoagulants, new hope. European Heart Journal 32:19, pages 2347-2349.
Crossref
Crossref
K. A. A. Fox, J. P. Piccini, D. Wojdyla, R. C. Becker, J. L. Halperin, C. C. Nessel, J. F. Paolini, G. J. Hankey, K. W. Mahaffey, M. R. Patel, D. E. Singer & R. M. Califf. (2011) Prevention of stroke and systemic embolism with rivaroxaban compared with warfarin in patients with non-valvular atrial fibrillation and moderate renal impairment. European Heart Journal 32:19, pages 2387-2394.
Crossref
Crossref
Manesh R. Patel, Kenneth W. Mahaffey, Jyotsna Garg, Guohua Pan, Daniel E. Singer, Werner Hacke, Günter Breithardt, Jonathan L. Halperin, Graeme J. Hankey, Jonathan P. Piccini, Richard C. Becker, Christopher C. Nessel, John F. Paolini, Scott D. Berkowitz, Keith A.A. Fox & Robert M. Califf. (2011) Rivaroxaban versus Warfarin in Nonvalvular Atrial Fibrillation. New England Journal of Medicine 365:10, pages 883-891.
Crossref
Crossref
C. Flaujac, C. Guinet & M. M. Samama. (2011) Dosage de l’activité anti-Xa des héparines de bas poids moléculaire (HBPM) du fondaparinux et des nouveaux anticoagulantsMeasurement of anti-Xa activity induced by low molecular weight heparins (LMWH), fondaparinux and new anticoagulants. Bio tribune magazine 38:1, pages 22-25.
Crossref
Crossref
Ismail Elalamy & Marie Solignac. (2011) Tests de coagulation et Xarelto® : indications sans recommandations. Le Praticien en Anesthésie Réanimation 15:3, pages H15-H18.
Crossref
Crossref
Meyer Michel Samama. (2011) The mechanism of action of rivaroxaban – an oral, direct Factor Xa inhibitor – compared with other anticoagulants. Thrombosis Research 127:6, pages 497-504.
Crossref
Crossref
C. Michael Gibson, Jessica L. Mega, Paul Burton, Shinya Goto, Freek Verheugt, Christoph Bode, Alexei Plotnikov, Xiang Sun, Nancy Cook-Bruns & Eugene Braunwald. (2011) Rationale and design of the Anti-Xa Therapy to Lower cardiovascular events in Addition to standard therapy in Subjects with Acute Coronary Syndrome–Thrombolysis in Myocardial Infarction 51 (ATLAS-ACS 2 TIMI 51) trial: A randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of rivaroxaban in subjects with acute coronary syndrome. American Heart Journal 161:5, pages 815-821.e6.
Crossref
Crossref
Lars Carl Borris. (2011) Design, findings and implications of the RECORD study program. Clinical Investigation 1:3, pages 423-428.
Crossref
Crossref
Meyer Michel Samama. (2011) Use of Low-Molecular-Weight Heparins and New Anticoagulants in Elderly Patients with Renal Impairment. Drugs & Aging 28:3, pages 177-193.
Crossref
Crossref
Frank Misselwitz, Scott D. Berkowitz & Elisabeth Perzborn. (2011) The discovery and development of rivaroxaban. Annals of the New York Academy of Sciences 1222:1, pages 64-75.
Crossref
Crossref
Mihai Gheorghiade, An Thyssen, Robert Zolynas, Venkatesh K. Nadar, Barry H. Greenberg, Mandeep Mehra, Xiang Sun, Hong Tian, Alexei N. Plotnikov & Paul Burton. (2011) Pharmacokinetics and pharmacodynamics of rivaroxaban and its effect on biomarkers of hypercoagulability in patients with chronic heart failure. The Journal of Heart and Lung Transplantation 30:2, pages 218-226.
Crossref
Crossref
A. HILLARP, F. BAGHAEI, I. FAGERBERG BLIXTER, K.M. GUSTAFSSON, L. STIGENDAL, M. STEN‐LINDER, K. STRANDBERG & T.L. LINDAHL. (2011) Effects of the oral, direct factor Xa inhibitor rivaroxaban on commonly used coagulation assays. Journal of Thrombosis and Haemostasis 9:1, pages 133-139.
Crossref
Crossref
Dhara Chaudhari, Rohit Bhuriya & Rohit Arora. (2011) Newer Anticoagulants as an Alternate to Warfarin in Atrial Fibrillation: A Changing Paradigm. American Journal of Therapeutics 18:1, pages e1-e11.
Crossref
Crossref
Elisabeth Perzborn, Susanne Roehrig, Alexander Straub, Dagmar Kubitza & Frank Misselwitz. (2010) The discovery and development of rivaroxaban, an oral, direct factor Xa inhibitor. Nature Reviews Drug Discovery 10:1, pages 61-75.
Crossref
Crossref
Jeffrey I. Weitz. (2011) Factor Xa and thrombin as targets for new oral anticoagulants. Thrombosis Research 127, pages S5-S12.
Crossref
Crossref
Hans-Juergen Rupprecht & Ralf Blank. (2010) Clinical Pharmacology of Direct and Indirect Factor Xa Inhibitors. Drugs, pages 1.
Crossref
Crossref
Meyer M. Samama, Satoshi Kunitada, Andŗe Oursin, Francois Depasse & Stan Heptinstall. (2010) Comparison of a direct Factor Xa inhibitor, edoxaban, with dalteparin and ximelagatran: A randomised controlled trial in healthy elderly adults. Thrombosis Research 126:4, pages e286-e293.
Crossref
Crossref
Christian T. RuffEugene Braunwald. (2010) Review: Will Warfarin Ever Be Replaced?. Journal of Cardiovascular Pharmacology and Therapeutics 15:3, pages 210-219.
Crossref
Crossref
Lars C. Borris. (2009) Rivaroxaban and dabigatran etexilate: two new oral anticoagulants for extended postoperative prevention of venous thromboembolism after elective total hip arthroplasty. Archives of Orthopaedic and Trauma Surgery 130:5, pages 583-589.
Crossref
Crossref
Walter Ageno. (2009) Rivaroxaban for venous thromboembolism prevention after total knee arthroplasty: RECORD3 findings. European Journal of Orthopaedic Surgery & Traumatology 19:8, pages 529-533.
Crossref
Crossref
Sylvia Haas. (2009) Rivaroxaban - an oral, direct Factor Xa inhibitor - lessons from a broad clinical study programme. European Journal of Haematology 82:5, pages 339-349.
Crossref
Crossref
Displaying 200 of 201 citing articles. Use the download link below to view the full list of citing articles.
Download full citations list